Loading…
← CockpitCompetitor Analysis › 002399.SZ Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class AOpen in the cockpit ↗

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A002399.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

World's largest producer of heparin active pharmaceutical ingredient, sourced from pig intestines and sold globally as a blood-thinner API.

≈ The world's dominant heparin API supplierMomentum strong 70
Mkt cap
$1.80B
US dollars, full cap
Free float
18%
of shares outstanding
$/day
$3.99M
20-day average traded
Fwd P/E
25.8×
forward earnings
ROIC−WACC
-2.4 pp
WACC 7.2%
Hurdle
-1 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥9.06
1D-0.2%
1W-2.0%
1M-3.6%
3M-15.6%
6M-12.4%
YTD-23.2%
1Y-25.2%
ATR %2.4%
52w lowhigh28.6% off high

What Shenzhen Hepalink Pharmaceutical does

World's largest producer of heparin active pharmaceutical ingredient, sourced from pig intestines and sold globally as a blood-thinner API.

Sells heparin API mainly to other drugmakers, which turn it into enoxaparin and other blood thinners, and also sells its own finished enoxaparin injections, which pay more per unit. Its US arm is Scientific Protein Laboratories, so raw-material and plant capacity sit in several countries.

In one line: The world's dominant heparin API supplier.

Products and services

  • Heparin sodium API
  • Low-molecular-weight heparin formulations

Customers

  • Global pharma companies making blood-thinner drugs

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Heparin API manufacturing

What could go right

  • Global anticoagulant drug demand

What could go wrong

  • Raw-material (pig intestine) supply/price volatility
  • Heparin price competition

Moat: narrow (scale, regulatory licence, installed base). Largest global heparin API capacity and FDA/EU-approved supply chain, hard to replicate at scale.

Headquarters: Shenzhen, China · Founded: 1998 · Employees: 2,150

Named competitors

  • Bioiberica private or unlisted
  • Techdow Pharma private or unlisted

Shenzhen Hepalink Pharmaceutical at a glance

Size Shenzhen Hepalink Pharmaceutical (002399.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.80B, the 1277th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.06 on 18 Nov 2026.

Performance Over six months the shares fell 12.4%, against -7.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue fell 6.0% over the last twelve months (peer median +6.7%); the operating margin is 7.7% (peer median 10.0%).

Valuation It trades at 25.8× forward earnings against a peer median of 19.1× (4th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.4 points below its cost of capital (7.2% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 95002399.SZ 89
Six months, rebased to 100: Shenzhen Hepalink Pharmaceutical against the median of its 20 peers (local-currency closes).

Shenzhen Hepalink Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥5.08BCN¥5.46BCN¥5.28BCN¥5.44BCN¥7.16B
Revenue growth—+3%-3%-24%—
Gross profitCN¥1.94BCN¥1.62BCN¥1.66BCN¥1.70BCN¥2.24B
EBITDAn/aCN¥886MCN¥1.05BCN¥125MCN¥1.30B
Net incomeCN¥190MCN¥349MCN¥647M-CN¥783MCN¥727M
Free cash flowCN¥1.96BCN¥1.61BCN¥2.28BCN¥26.5M-CN¥844M
Capital expenditureCN¥106MCN¥121MCN¥203MCN¥445MCN¥222M
Total debtCN¥3.10BCN¥2.97BCN¥3.54BCN¥5.56BCN¥6.46B

Quarterly statements and history in the cockpit →

Shenzhen Hepalink Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%-10%0%+10%301015RARE3933ZYME000028ETON605507600664300573AGIODMP000908COHANCE600211300009PFIZERNATCOPHARM688166ALIVUSMAZE002399.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shenzhen Hepalink Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×301015RARE3933ZYME000028ETON600664300573DMPCOHANCEPFIZERNATCOPHARM688166002399.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shenzhen Hepalink Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%3010153933000028ETON688166002399.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shenzhen Hepalink Pharmaceutical is the large dot.

Shenzhen Hepalink Pharmaceutical competitors and peer comparison

How Shenzhen Hepalink Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shenzhen Hepalink Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002399.SZPeer medianRank in peer set
1-month return-3.6%+0.1%8th lowest of 21
6-month return-12.4%-7.3%10th lowest of 21
Distance from 52-week high-28.6%-33.7%9th highest of 21
Revenue growth (TTM)-6.0%+6.7%6th lowest of 21
Operating margin7.7%10.0%10th lowest of 21
Forward P/E25.8×19.1×4th most expensive of 18
Growth the price implies (Req g, 7 yrs)-0.7%6.7%6th least demanding of 15
Growth delivered (Del g)+0.5%+8.1%lowest of 15
Hurdle (Req g minus delivered)-1.2 pp-9.0 pp6th most demanding of 15
ROIC minus cost of capital-2.4 pp+2.4 pp10th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shenzhen Hepalink Pharmaceutical 002399.SZChina$1.80B-12%-6%8%25.8×-0.7%+0.5%
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a

Questions

Who are Shenzhen Hepalink Pharmaceutical's main competitors?
Named competitors: Bioiberica (private or unlisted), Techdow Pharma (private or unlisted). The cockpit's measured peer set (industry) also includes Qingdao Baheal Medical (301015.SZ), Ultragenyx Pharmaceutical (RARE), United Laboratories International (3933.HK), Zymeworks (ZYME), China National Accord Medicines (000028.SZ), Eton Pharmaceuticals (ETON).
Is Shenzhen Hepalink Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 25.8× against a peer median of 19.1×, 4th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Shenzhen Hepalink Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -12.4% against -7.3% for the median peer; over one year -25.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.